Abstracts tagged "psoriasis"

Abstract Number: 1737 • 2015 ACR/ARHP Annual Meeting
Increased Osteoclast Precursors with an Elevated DC-STAMP Expression May Identify Psoriasis Patients at Risk for Psoriatic Arthritis
Yahui Grace Chiu¹, Sutha Shanmugarajah², Dongge Li³, Megan Freiburger⁴, Sharon Moorehead⁵, Dafna Gladman⁶ and Christopher T. Ritchlin⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Toronto Western Hospital, Toronto, ON, Canada, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Biology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁷Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop into psoriatic arthritis (PsA) within 10 years. This Ps-to-PsA transition paradigm provides a unique opportunity to recognize…
Abstract Number: 2063 • 2015 ACR/ARHP Annual Meeting
The Survival Impact of Statins in Psoriasis and Psoriatic Arthritis: A General Population-Based Cohort Study
Sian Yik Lim¹, Na Lu² and Hyon K. Choi², ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Given their lipid-lowering and anti-inflammatory properties, statins may have dual cardioprotective and anti-rheumatic benefits in psoriasis or psoriatic arthritis. These effects may confer survival…
Abstract Number: 2065 • 2015 ACR/ARHP Annual Meeting
Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis
Vinod Chandran¹, Daniela Cretu^2,3, Lisa Gao⁴, Kun Liang⁴, Antoninus Soosaipillai³ and Eleftherios Diamandis^2,3,5, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ³Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada
Background/Purpose: There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients. Therefore identifying soluble biomarkers for PsA will help in screening psoriasis…
Abstract Number: 2806 • 2015 ACR/ARHP Annual Meeting
Bacterial Skin Microbiome in Psoriatic Arthritis Ã¢â‚¬â€œ Pilot Data from Psoriatic Plaques on Dry Skin Sites from Patients with Psoriasis (PsC) and Psoriatic Arthritis (PsA)
Madhura Castelino¹, Stephen Eyre², Mauro Tutino², John Moat³, Paul Martin², Umer Ijaz⁴, Christopher Quince⁵, Pauline Ho¹, Mathew Upton⁶ and Anne Barton^1,7, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ³Microbiology and Virology Unit, University of Manchester, Manchester, United Kingdom, ⁴School of Engineering, University of Glasgow, Glasgow, United Kingdom, ⁵Warwick Medical School, University of Warwick, Coventry, United Kingdom, ⁶Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom
Background/Purpose: In complex traits like psoriasis (PsC) and psoriatic arthritis (PsA) interactions between genetics and environmental factors are thought to result in the development of…
Abstract Number: 632 • 2014 ACR/ARHP Annual Meeting
IL-23 Mediates Psoriasis-like Inflammation in the SKG Mouse Model of Spondyloarthropathy
Helen Benham¹, Linda Rehaume¹, Athan Baillet¹, Zaied Bhuyan¹, Jaclyn Bowman¹, Dimeng Pang¹, Kristine Kikly², Geoffrey Strutton³, Matthew Brown¹ and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, ³Department of Pathology, Princess Alexandra Hospital, Brisbane, Australia
Background/Purpose Psoriasis (Ps) is a common immune-mediated inflammatory skin disease and is a well- recognised extra-articular manifestation of the spondyloathopathies (SpA). Genetic studies implicate IL-23…
Abstract Number: 628 • 2014 ACR/ARHP Annual Meeting
The Predictive Value of Cardiovascular and Metabolic Biomarkers for Progression of Atherosclerosis in Psoriatic Disease
Lihi Eder¹, Fatima Abji¹, Cheryl Rosen², Vinod Chandran¹ and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose The pathophysiologic mechanisms underlying the accelerated atherosclerosis in patients with psoriatic disease (PsD) are unknown. We aimed to investigate candidate pathways involved in this…
Abstract Number: 537 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial
Alice B. Gottlieb¹, Philip J. Mease², Iain B. McInnes³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Proton Rahman⁶, Peter Nash⁷, Luminita Pricop⁸, Jiacheng Yuan⁹, Hanno Richards¹⁰ and Shephard Mpofu¹¹, ¹Tufts Medical Center, Boston, MA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁷University of Queensland, Brisbane, Australia, ⁸Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Reducing the burden of skin manifestations of psoriatic arthritis (PsA) is an important aspect of disease management. Secukinumab, a human anti–IL-17A monoclonal antibody, has…
Abstract Number: 139 • 2014 ACR/ARHP Annual Meeting
Ultrasound Enthesitis in Primary Care Psoriasis Patients with Musculoskeletal Complaints
M. van der Ven¹, M.C. Karreman¹, A.E.a.M. Weel^1,2, I. Tchetverikov³, M. Vis⁴, T.E.C. Nijsten⁵, J.M.W. Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Erasmus University Medical Center, Rotterdam, Netherlands, ⁵Dermatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: Psoriasis patients with enthesitis can classify as psoriatic arthritis since the introduction of the CASPAR classification criteria in 2006. However, the presence of a…
Abstract Number: 2359 • 2014 ACR/ARHP Annual Meeting
CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis
Iris Hecht¹, Kay McNamee², Aviad Keren³, Joseph R. Podojil⁴, Ilan Vaknin¹, Anat Oren¹, Galit Rotman¹, Eyal Neria¹, Stephen D. Miller⁴, Amos Gilhar³ and Richard O. Williams², ¹Compugen Ltd., Tel Aviv, Israel, ²Kennedy Institute of Rheumatology, Oxford University, Oxford, United Kingdom, ³Technion Institute of Technology, Haifa, Israel, ⁴Microbiology-Immunology, Northwestern University, Chicago, IL
Background/Purpose CGEN-15001 is an Fc-fusion protein consisting of the extracellular domain of a novel B7-like protein, discovered based on shared family characteristics. CGEN-15001 inhibits T…
Abstract Number: 1850 • 2014 ACR/ARHP Annual Meeting
The Incidence and Risk Factors for Psa in Patients with Psoriasis – a Prospective Cohort Study
Lihi Eder¹, Amir Haddad¹, Hua Shen², Cheryl Rosen³, Vinod Chandran¹, Richard J. Cook² and Dafna D. Gladman⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose There are limited data regarding the incidence of PsA in patients with psoriasis. We aimed to estimate the incidence of PsA in a prospective…
Abstract Number: 1567 • 2014 ACR/ARHP Annual Meeting
The Spectrum of Autoimmune Ophthalmic Manifestations in Psoriatic Disease
Sergio Schwartzman¹, Anton Kolomeyer² and David Chu³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Ophthalmology, University of Pittsburgh, Pittsburgh, PA, ³Ophthalmology, Rutgers, Newark, NJ
Background/Purpose: Psoriatic disease is characterized by the presence of psoriasis with or without an association of extra-dermal manifestations. Inflammatory forms of arthritis are the most…
Abstract Number: 1581 • 2014 ACR/ARHP Annual Meeting
Inflammatory Back Pain in Psoriasis and Psoriatic Arthritis Is Suggestive of Undiagnosed Spondyloarthropathies
Majed Khraishi¹, Heather Jones^2,3 and Annette Szumski⁴, ¹Clinical Professor of Medicine (Rheumatology), Memorial University of Newfoundland, St. John's, NF, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Patients with psoriasis (Ps) and/or psoriatic arthritis (PsA) may have clinical features suggestive of axial skeletal abnormalities and should be assessed for the presence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].